OBJECTIVE: Accurate pathologic restaging of N2 stations after neoadjuvant therapy in stage IIIA (N2) non-small cell lung cancer is needed. METHODS: A prospective multi-institutional trial was designed to judge the feasibility of videothoracoscopy to restage the ipsilateral nodes in mediastinoscopy-proven stage IIIA (N2) non-small cell lung cancer after 2 cycles of platinum-based chemotherapy and/or 40 Gy or more of radiotherapy. The goals included biopsy of 3 negative N2 node stations or to identify 1 positive N2 node or pleural carcinomatosis. RESULTS: Ten institutions accrued 68 subjects. Of the 68 subjects, 46 (68%) underwent radiotherapy and 66 (97%) underwent chemotherapy. Videothoracoscopy successfully met the prestudy feasibility in 27 patients (40%): 3 negative stations confirmed at thoracotomy in 7, persistent stage N2 disease in 16, and pleural carcinomatosis in 4. In 20 procedures (29%), no N2 disease was found, 3 stations were not biopsied because of unanticipated nodal obliteration. Thus, 47 videothoracoscopy procedures (69%, 95% confidence interval, 57%-80%) restaged the mediastinum. Videothoracoscopy was unsuccessful in 21 patients (31%) because the procedure had to be aborted (n = 11) or because of false-negative stations (n = 10). Of the 21 failures, 15 were right-sided, and 10 had a positive 4R node. The sensitivity of videothoracoscopy was 67% (95% confidence interval, 47%-83%), and the negative predictive value was 73% (95% confidence interval, 56%-86%) if patients with obliterated nodal tissue were included. The sensitivity was 83% (95% confidence interval, 63%-95%) and the negative predictive value was 64% (95% confidence interval, 31%-89%) if those patients were excluded. The specificity was 100%. One death occurred after thoracotomy. CONCLUSIONS: Videothoracoscopy restaging was "feasible" in this prospective multi-institutional trial and provided pathologic specimens of the ipsilateral nodes. Videothoracoscopy restaging was limited by radiation and the 4R nodal station.
OBJECTIVE: Accurate pathologic restaging of N2 stations after neoadjuvant therapy in stage IIIA (N2) non-small cell lung cancer is needed. METHODS: A prospective multi-institutional trial was designed to judge the feasibility of videothoracoscopy to restage the ipsilateral nodes in mediastinoscopy-proven stage IIIA (N2) non-small cell lung cancer after 2 cycles of platinum-based chemotherapy and/or 40 Gy or more of radiotherapy. The goals included biopsy of 3 negative N2 node stations or to identify 1 positive N2 node or pleural carcinomatosis. RESULTS: Ten institutions accrued 68 subjects. Of the 68 subjects, 46 (68%) underwent radiotherapy and 66 (97%) underwent chemotherapy. Videothoracoscopy successfully met the prestudy feasibility in 27 patients (40%): 3 negative stations confirmed at thoracotomy in 7, persistent stage N2 disease in 16, and pleural carcinomatosis in 4. In 20 procedures (29%), no N2 disease was found, 3 stations were not biopsied because of unanticipated nodal obliteration. Thus, 47 videothoracoscopy procedures (69%, 95% confidence interval, 57%-80%) restaged the mediastinum. Videothoracoscopy was unsuccessful in 21 patients (31%) because the procedure had to be aborted (n = 11) or because of false-negative stations (n = 10). Of the 21 failures, 15 were right-sided, and 10 had a positive 4R node. The sensitivity of videothoracoscopy was 67% (95% confidence interval, 47%-83%), and the negative predictive value was 73% (95% confidence interval, 56%-86%) if patients with obliterated nodal tissue were included. The sensitivity was 83% (95% confidence interval, 63%-95%) and the negative predictive value was 64% (95% confidence interval, 31%-89%) if those patients were excluded. The specificity was 100%. One death occurred after thoracotomy. CONCLUSIONS: Videothoracoscopy restaging was "feasible" in this prospective multi-institutional trial and provided pathologic specimens of the ipsilateral nodes. Videothoracoscopy restaging was limited by radiation and the 4R nodal station.
Authors: D Meersschaut; F Vermassen; A Brutel de la Rivière; P J Knaepen; J M Van den Bosch; R Vanderschueren Journal: Ann Thorac Surg Date: 1992-01 Impact factor: 4.330
Authors: R Bueno; W G Richards; S J Swanson; M T Jaklitsch; J M Lukanich; S J Mentzer; D J Sugarbaker Journal: Ann Thorac Surg Date: 2000-12 Impact factor: 4.330
Authors: Tim Akhurst; Robert J Downey; Michelle S Ginsberg; Mithat Gonen; Manjit Bains; Robert Korst; Robert J Ginsberg; Valerie W Rusch; Steven M Larson Journal: Ann Thorac Surg Date: 2002-01 Impact factor: 4.330
Authors: Jeffrey L Port; Michael S Kent; Robert J Korst; Roger Keresztes; Matthew A Levin; Nasser K Altorki Journal: Ann Thorac Surg Date: 2004-01 Impact factor: 4.330
Authors: Robert James Cerfolio; Buddhiwardhan Ojha; Sudipto Mukherjee; Amanda Harrison Pask; Cynthia Sale Bass; Charles R Katholi Journal: J Thorac Cardiovasc Surg Date: 2003-04 Impact factor: 5.209
Authors: Felix J F Herth; Jouke T Annema; Ralf Eberhardt; Kazuhiro Yasufuku; Armin Ernst; Mark Krasnik; Robert C Rintoul Journal: J Clin Oncol Date: 2008-06-02 Impact factor: 44.544
Authors: K S Albain; V W Rusch; J J Crowley; T W Rice; A T Turrisi; J K Weick; V A Lonchyna; C A Presant; R J McKenna; D R Gandara Journal: J Clin Oncol Date: 1995-08 Impact factor: 44.544
Authors: M Majem; J Hernández-Hernández; F Hernando-Trancho; N Rodríguez de Dios; A Sotoca; J C Trujillo-Reyes; I Vollmer; R Delgado-Bolton; M Provencio Journal: Clin Transl Oncol Date: 2019-06-06 Impact factor: 3.405
Authors: Chi-Fu Jeffrey Yang; Syed M Adil; Kevin L Anderson; Robert Ryan Meyerhoff; Ryan S Turley; Matthew G Hartwig; David H Harpole; Betty C Tong; Mark W Onaitis; Thomas A D'Amico; Mark F Berry Journal: Eur J Cardiothorac Surg Date: 2015-12-30 Impact factor: 4.191
Authors: Chi-Fu Jeffrey Yang; Brian C Gulack; Lin Gu; Paul J Speicher; Xiaofei Wang; David H Harpole; Mark W Onaitis; Thomas A D'Amico; Mark F Berry; Matthew G Hartwig Journal: J Thorac Cardiovasc Surg Date: 2015-07-02 Impact factor: 5.209
Authors: Paul E Van Schil; Lawek Berzenji; Suresh K Yogeswaran; Jeroen M Hendriks; Patrick Lauwers Journal: Front Oncol Date: 2017-10-26 Impact factor: 6.244